Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF) (2022 - 2026)
Orchestra BioMed Holdings' (OBIO) quarterly Depreciation & Amortization (CF) came in at $90000.0 in Q1 2026, up 8.43% year-on-year from $83000.0 in Q1 2025, and up 9.76% on a QoQ basis from $82000.0 in Q4 2025.
Orchestra BioMed Holdings (OBIO) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $90000.0 in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 8.43% year-over-year to $90000.0 in Q1 2026; TTM through Mar 2026 was $334000.0, a 5.36% increase from a year earlier, with the FY2025 full-year figure at $327000.0, up 6.17% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $90000.0, up from $82000.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for OBIO reached as high as $90000.0 in Q1 2026 and fell as low as $48000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $72588.2 across 5 years, with a median of $74000.0 in 2024.
- Across the five-year window, Depreciation & Amortization (CF) soared 47.92% in 2023 and declined 2.38% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $70000.0 in 2022, then rose by 2.86% to $72000.0 in 2023, then advanced by 16.67% to $84000.0 in 2024, then retreated by 2.38% to $82000.0 in 2025, then increased by 9.76% to $90000.0 in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $90000.0 in Q1 2026, $82000.0 in Q4 2025, and $81000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Orchestra BioMed Holdings | 228.31 Mn | 143.68 Mn | 78,000.00 | 90,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 90,000.00 |
| Mar 31, 2026 | 90,000.00 |
| Dec 31, 2025 | 82,000.00 |
| Dec 31, 2025 | 82,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Sep 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Mar 31, 2025 | 83,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 74,000.00 |
| Jun 30, 2024 | 74,000.00 |
| Mar 31, 2024 | 74,000.00 |
| Mar 31, 2024 | 74,000.00 |
| Dec 31, 2023 | 72,000.00 |
| Dec 31, 2023 | 72,000.00 |